Oscotec Inc - Asset Resilience Ratio
Oscotec Inc (039200) has an Asset Resilience Ratio of 65.38% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Oscotec Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Oscotec Inc's Asset Resilience Ratio has changed over time. See Oscotec Inc (039200) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Oscotec Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 039200 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩145.37 Billion | 65.38% |
| Total Liquid Assets | ₩145.37 Billion | 65.38% |
Asset Resilience Insights
- Very High Liquidity: Oscotec Inc maintains exceptional liquid asset reserves at 65.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oscotec Inc Industry Peers by Asset Resilience Ratio
Compare Oscotec Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
|
Kolon Life Science Inc
KQ:102940 |
Pharmaceuticals | 1.22% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 13.09% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
Annual Asset Resilience Ratio for Oscotec Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Oscotec Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 40.42% | ₩92.90 Billion ≈ $62.95 Million |
₩229.85 Billion ≈ $155.77 Million |
-12.06pp |
| 2024-12-31 | 52.48% | ₩89.62 Billion ≈ $60.74 Million |
₩170.78 Billion ≈ $115.73 Million |
-21.05pp |
| 2023-12-31 | 73.53% | ₩97.48 Billion ≈ $66.06 Million |
₩132.58 Billion ≈ $89.85 Million |
+1.38pp |
| 2022-12-31 | 72.14% | ₩103.70 Billion ≈ $70.27 Million |
₩143.74 Billion ≈ $97.41 Million |
+42.36pp |
| 2021-12-31 | 29.78% | ₩14.58 Billion ≈ $9.88 Million |
₩48.97 Billion ≈ $33.18 Million |
-7.04pp |
| 2020-12-31 | 36.83% | ₩28.13 Billion ≈ $19.06 Million |
₩76.39 Billion ≈ $51.77 Million |
-36.00pp |
| 2019-12-31 | 72.82% | ₩52.72 Billion ≈ $35.73 Million |
₩72.39 Billion ≈ $49.06 Million |
+22.07pp |
| 2018-12-31 | 50.75% | ₩35.66 Billion ≈ $24.17 Million |
₩70.26 Billion ≈ $47.61 Million |
-7.86pp |
| 2017-12-31 | 58.62% | ₩23.77 Billion ≈ $16.11 Million |
₩40.54 Billion ≈ $27.48 Million |
+34.77pp |
| 2016-12-31 | 23.84% | ₩9.73 Billion ≈ $6.59 Million |
₩40.81 Billion ≈ $27.66 Million |
-2.28pp |
| 2015-12-31 | 26.12% | ₩12.93 Billion ≈ $8.76 Million |
₩49.50 Billion ≈ $33.54 Million |
+9.67pp |
| 2014-12-31 | 16.45% | ₩5.97 Billion ≈ $4.04 Million |
₩36.27 Billion ≈ $24.58 Million |
-3.15pp |
| 2013-12-31 | 19.61% | ₩7.38 Billion ≈ $5.00 Million |
₩37.65 Billion ≈ $25.51 Million |
-6.59pp |
| 2012-12-31 | 26.19% | ₩11.28 Billion ≈ $7.64 Million |
₩43.05 Billion ≈ $29.17 Million |
+14.28pp |
| 2011-12-31 | 11.91% | ₩5.72 Billion ≈ $3.87 Million |
₩47.98 Billion ≈ $32.51 Million |
-- |
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more